Dr Reddy’s reported “growth across all markets” as the company saw a 12% jump in revenues in its global generics segment to INR154.4bn ($2.12bn) for financial year 2021, as the company’s total sales rose by 9% to INR189.7bn. Moreover, the company witnessed double-digit growth in Europe and India during the year, which the company credited to its slate of launches.
Commenting on the results, Erez Israeli, CEO of Dr Reddy’s said, “Our generics business has managed to grow for the...




